Recently, sotorasib, a KRAS inhibitor against KRAS p.G12C, has emerged with promising results in pretreated non-small cell lung cancer, with an ORR of 37.1% and DCR of 80.6%. Here, KRAS is linked to non-small cell lung carcinoma.